Is PMOS the Same as PCOS? (& Exploring The Link To Gut Health)

PMOS (Polyendocrine Metabolic Ovarian Syndrome) and PCOS (Polycystic Ovary Syndrome) are closely linked terms that describe a complex hormonal and metabolic condition affecting the ovaries, and wider metabolic dysfunction pathways, often contributing to irregular periods, persistent fatigue and difficulties with weight management. 

As of May 2026, growing discussions around biohacking, personalised healthcare and women’s metabolic health have increased interest in whether PMOS is simply a new name for PCOS or a broader understanding of the condition itself. 

The insights in this article are provided by Vivere’s Head of Nutrition, Yusra Serdaroglu Aydin, a registered dietitian with a background in nutrition, food engineering and culinary arts. Her approach is grounded in science and shaped by a strong understanding of personalised nutrition and the human microbiome.

PMOS is largely considered an updated and more medically accurate term for PCOS that better reflects the condition’s hormonal, metabolic and inflammatory nature, including its growing connection to gut health.

• What does PMOS stand for? 

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome, a term designed to better represent the diagnostic criteria, biological condition, hormonal systems and metabolic systems involved in PCOS.

• Does the gut affect PMOS? 

Insulin resistance and inflammation are recognised features in many people with PMOS, and dysbiosis is an emerging area of research.

• Has the diagnosis process changed? 

The diagnosis process for PMOS remains similar to PCOS, although healthcare professionals are increasingly considering broader metabolic and inflammatory markers.

• Does the gut-ovary axis affect PMOS? 

Research into the gut microbiome suggests the gut may influence hormone regulation, energy metabolism and reproductive health through the gut-ovary axis.

• Does improving gut health help with PMOS and its symptoms? 

Improving gut health through targeted nutrition and lifestyle support may help improve symptom management, sustained energy levels and long-term wellness.

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome, which highlights the hormonal systems, metabolic systems and broader biological conditions involved in the disorder.

The term was introduced to move beyond the limitations of the older PCOS label, which focused heavily on ovarian cysts despite many people not having ovarian cysts. PMOS reflects the fact that the condition affects multiple endocrine pathways and metabolic functions, including insulin regulation, inflammation and reproductive hormone balance. Current diagnostic approaches already recognise that PCOS/PMOS involves more than ovarian appearance alone.

The diagnosis process for PMOS is currently very similar to PCOS diagnosis, although clinicians may place more emphasis on metabolic systems and inflammation.

Doctors still assess symptoms such as irregular periods, signs of androgen excess and ovulatory dysfunction. Blood tests, medical history and imaging may still be used as part of the diagnostic criteria. However, as understanding evolves, healthcare providers are also paying closer attention to insulin resistance, lipid profiles and broader hormonal systems that contribute to long-term health risks.

Gut health has become relevant to PMOS because emerging evidence links dysbiosis and systemic inflammation to hormone imbalance and metabolic dysfunction.

Researchers now believe the gut microbiome may influence many things from insulin sensitivity to androgen production. The connection between gut bacteria and reproductive health is increasingly referred to as the gut-ovary axis. Changes in the microbiome may contribute to persistent inflammation, altered energy metabolism and worsening symptoms associated with PMOS.

The shift from PCOS to PMOS reflects growing recognition within the global medical community that the condition involves far more than the ovaries alone [1] [2] [3].

Researchers from institutions including Monash University and organisations such as Verity, a UK charity supporting people with PCOS, have supported discussions around renaming the condition to improve clinical understanding and patient care. The original term "Polycystic Ovary Syndrome" has long been criticised because many patients do not actually develop ovarian cysts. Instead, ultrasound scans often reveal immature ovarian follicles that fail to mature and ovulate properly.

The new terminology also places greater emphasis on metabolic dysfunction and endocrine disruption. PMOS better reflects the influence of androgens such as testosterone, changes in Luteinising Hormone (LH), insulin resistance and abnormal lipid profiles, including elevated cholesterol levels.

Many people with the condition experience anovulation, irregular menstrual cycles and fertility challenges. Others may primarily struggle with fatigue, weight changes, skin concerns or metabolic complications. Some individuals may still receive treatment involving the contraceptive pill to help regulate hormones and menstrual cycles, but growing awareness of metabolic health means treatment discussions are becoming more comprehensive.

Importantly, the name change does not mean the condition itself has suddenly changed. Rather, it reflects a better scientific understanding of how interconnected reproductive hormones, metabolism and inflammation truly are.

The gut-ovary axis describes the communication pathway between the gastrointestinal microbiome and the reproductive system [5] [6] [7].

Scientists increasingly believe the gut microbiome plays an important role in hormone metabolism, inflammation and reproductive function. Research suggests people with PMOS often have lower microbial alpha-diversity, meaning they may have a less varied and resilient microbiome compared to individuals without the condition.

The gut microbiome may also influence bile acid metabolism and testosterone production. Since hormones and gut bacteria interact continuously, disruptions within the gut environment may worsen insulin resistance and inflammatory pathways linked to PMOS symptoms.

Several bacterial groups appear to influence inflammation, metabolism and reproductive hormone regulation in PMOS.

Beneficial bacteria, including Lactobacillus and Bifidobacterium, are associated with healthier gut barrier function and reduced inflammation. Meanwhile, imbalances involving Prevotella and Bacteroides vulgatus have been associated with altered metabolic responses and hormonal disruption in some research studies.

Although research is still developing, these findings support the idea that microbial diversity may play an important role in overall hormonal resilience.

Dysbiosis may contribute to insulin resistance by weakening the intestinal lining and increasing inflammatory activity throughout the body.

When the gut barrier becomes compromised, intestinal permeability, sometimes called leaky gut, may increase. This can allow lipopolysaccharides (LPS) and other bacterial toxins to move from the gut into the bloodstream. Once there, they may activate the immune system and trigger an inflammatory response.

Chronic inflammation can interfere with insulin receptors and impair energy metabolism, making it harder for the body to regulate blood sugar efficiently. This process is strongly linked to insulin resistance, which is an important feature in many people with PMOS.

Protective compounds such as butyrate and other short-chain fatty acids (SCFA) help support gut barrier integrity and reduce inflammation. These compounds are produced when beneficial bacteria ferment dietary fibre in the gut.

Supporting PMOS and gut health involves improving the gut microbiome while also addressing broader metabolic and inflammatory factors [8] [9].

Many healthcare professionals now recommend a more holistic approach that combines nutrition, movement, sleep, stress management and targeted metabolic support. Prebiotic fibres and fermented foods may help support bacterial diversity, while personalised strategies may improve long-term symptom management.

Vivere supports this approach through advanced gut microbiome testing, AI-powered nutrition insights and biohacking tools designed to help individuals better understand their own biology and take dedicated actions. This may help support sustained energy levels, digestive resilience and long-term wellness goals.

Simple dietary changes may help improve microbial diversity, insulin sensitivity and overall metabolic balance.

Prebiotic fibres help feed beneficial bacteria within the gut microbiome.

Foods such as garlic, onions, leeks and asparagus naturally contain prebiotic compounds that support bacterial growth. These foods are widely available in UK supermarkets, including Tesco and Sainsbury’s. Increasing fibre intake gradually may help improve digestive tolerance and support better metabolic outcomes over time.

Fermented foods may help introduce beneficial bacteria that support gut barrier function and microbial diversity.

Options such as kefir, live yoghurt and unpasteurised sauerkraut contain live cultures that may positively influence the gut environment. Choosing products with minimal added sugars may provide greater metabolic benefits for individuals with insulin resistance.

Some medications used for PMOS may influence digestion, appetite and metabolic health.

Metformin remains one of the most commonly prescribed NHS treatments for insulin resistance associated with PMOS. While it may improve insulin sensitivity, some people experience gastrointestinal side effects, including bloating or diarrhoea. Supporting gut health alongside medication may help improve tolerance and overall well-being.

Existing diagnosis records within the UK healthcare system may not automatically change immediately.

Many NHS pathways and treatment plan structures still use the term PCOS. However, healthcare professionals are increasingly aware of the newer PMOS terminology and the broader metabolic understanding behind it. The practical aspects of care and symptom management are unlikely to change dramatically in the short term.

No. Improving gut health may support symptom management, but PMOS is still considered a chronic condition.

Addressing the gut-ovary axis may help reduce systemic inflammation and improve insulin sensitivity, which can positively affect symptoms such as fatigue, weight-management difficulties and metabolic markers. However, remission looks different for each individual, and there is currently no confirmed permanent cure.

NAD+ (Nicotinamide Adenine Dinucleotide) may help support cellular energy production and metabolic health.

NAD+ plays an important role in mitochondrial repair, metabolic function and inflammation control. Some emerging research suggests supporting cellular energy pathways may benefit people experiencing chronic fatigue, low-grade inflammation and gut dysbiosis linked to PMOS. While research is still evolving, NAD+ therapies, such as NAD+ injections and supplements are increasingly explored within personalised wellness and biohacking approaches.

“PMOS should be viewed as a complex women’s health condition involving interconnected metabolic, endocrine and reproductive pathways, rather than a disorder isolated to the ovaries alone. Supporting microbial diversity, maintaining gut barrier function and addressing related factors such as insulin resistance and inflammation may help support symptom management and long-term wellbeing. While no single dietary strategy works for everyone, personalised nutrition and microbiome-informed care may offer a more comprehensive way to support overall health.”

Vivere helps you take control of your health with personalised insights from state-of-the-art gut microbiome testing, nutritional guidance, science-backed biohacking supplements, NAD+ supplementation and expert support. Sign up today and start living better, for longer.

[1] Name Change from “PCOS” to “PMOS” – Investigating the Association between Polyendocrine Metabolic Ovarian Syndrome and Eating Disorder Symptoms

[2] Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide | EurekAlert!

[3] Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process - PubMed

[5] Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome - PubMed

[6] Gut-ovary axis in polycystic ovary syndrome: mechanistic insights and gut microbiota-targeted therapeutic strategies - PubMed

[7] Causal relationship between gut microbiota and polycystic ovary syndrome: a literature review and Mendelian randomization study - Frontiers

[8] Gut microbiota alterations reveal potential gut–brain axis changes in polycystic ovary syndrome

[9] Intersection of Polycystic Ovary Syndrome and the Gut Microbiome | Journal of the Endocrine Society | Oxford Academic